Brief: Jhbp Cy Says China's Nmpa Accepted New Drug Application For Gb491 (Lerociclib) With Fluvestran
28/03/2023 11:39
March 28 (Reuters) - Genor Biopharma Holdings Ltd
6998.HK :
* CHINA'S NMPA OFFICIALLY ACCEPTED NEW DRUG APPLICATION FOR
GB491
(LEROCICLIB) IN COMBINATION WITH FLUVESTRAN
Source text for Eikon: ID:nHKS7K2CVY
Further company coverage: 6998.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Edding Genor group
See all newsBrief: Edding Genor Says CEO Initiates Plan To Purchase Additional Shares In Open Market
Brief: Edding Genor Posts Net Profit Increased To Rmb399.3 Million In 2025
Brief: Genor Biopharma Says NMPA Granted New Drug Application Approval For Lerociclib (Gb491)
Brief: Genor Biopharma, Its Unit & Edding Group Entered Into Merger Agreement
Brief: Genor Biopharma Says Guo Feng Tendered His Resignation As Chairman